MWNA
FBRX

Marshall Wace North America’s Forte Biosciences FBRX Stock Holding History

Marshall Wace North America’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-474
Closed -$398K – 1513
2021
Q2 		$398K Sell
474
-560
-54% -$505K ﹤0.01% 1222
2021
Q1 		$885K Buy
+1,034
New +$847K ﹤0.01% 1077
2019
Q1 		– Sell
-60
Closed -$186K – 1662
2018
Q4 		$186K Buy
+60
New +$258K ﹤0.01% 967

Other funds holding FBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.88B AUM 35.68% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Marshall Wace North America's FBRX Position: Q3 2021 in Review

Marshall Wace North America sold out of Forte Biosciences (FBRX) in Q3 2021, closing a stake of 474 shares — an estimated $398K sold.

Marshall Wace North America first reported a position in FBRX in Q4 2018 and held it in 3 quarters. The position peaked at $885K in Q1 2021. 57 funds tracked by Wall St. Rank hold FBRX as of Q3 2021.

  • Marshall Wace North America reported no remaining Forte Biosciences position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 474 Forte Biosciences shares in Q3 2021, an estimated $398K.
  • Marshall Wace North America first reported a position in Forte Biosciences in Q4 2018 and held it in 3 quarters.
  • Marshall Wace North America's Forte Biosciences position peaked at $885K in Q1 2021.
  • 57 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.